Corcept Reports Favorable Survival and Response Data in Ovarian Cancer Study

What happened

Corcept Therapeutics reported results from Part A of its Phase 2 BELLA trial, which tested Lifyorli with nab-paclitaxel and bevacizumab in 95 women with recurrent, platinum-resistant ovarian cancer. The trial showed a median progression-free survival of 7.2 months and an overall response rate of 59%.

Confirmed

Global impact / market context

Better survival and response data could strengthen Lifyorli's case with doctors and regulators, potentially supporting wider use in platinum-resistant ovarian cancer. That matters for Corcept because successful drugs can raise treatment revenue and fund future research, though the small single-arm trial limits certainty.

Analyst inference

The BELLA results compare favorably with the Phase 3 ROSELLA study, where median progression-free survival was 5.4 months for Lifyorli plus nab-paclitaxel. Investors often weigh early single-arm trial data against larger randomized studies, so the comparison may shape expectations for Lifyorli's commercial prospects in ovarian cancer.

Analyst inference

What to watch

1. Corcept has not yet reached median overall survival in BELLA; 88% of participants remained alive at six months, compared with 82% and 77% in the ROSELLA cohorts. Confirmed
2. Investors should watch for further BELLA data, including overall survival updates and any plans to present complete Part A results, which could clarify how durable the observed responses are. Proposed
3. Because BELLA is a single-arm, open-label trial, regulators may want randomized confirmation before broad approval, so the design of any later-stage study and its timelines are key to watch. Analyst inference

Evidence

• Original source link unavailable